 CAMBRIDGE, Mass., Dec. 11, 2020 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss interim data from the Phase 1 portion of the TC-210 Phase 12 clinical trial for patients with mesothelin-expressing solid tumors in a premarket press release and webcast to be held on Monday, December 14th, 2020. 